May 13, 2026 05:39PM

Aug 14, 2025 07:55AM

Aug 13, 2025 06:46PM

Jul 21, 2025 07:55AM

Jul 8, 2025 07:52AM

Jul 2, 2025 06:10AM

Jun 26, 2025 07:55AM ZyVersa Therapeutics (ZVSA) Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator VAR 200’s Phase 2a Clinical Trial

Jun 25, 2025 07:55AM

May 20, 2025 08:52AM

May 13, 2025 04:49PM

May 7, 2025 07:57AM

Apr 24, 2025 07:57AM

Apr 8, 2025 07:57AM

Mar 18, 2025 07:57AM ZyVersa Therapeutics (ZVSA) Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Mode

Mar 12, 2025 07:57AM

Mar 6, 2025 08:00AM

Mar 5, 2025 07:52AM

Nov 20, 2024 07:56AM

Nov 5, 2024 07:06AM

Oct 22, 2024 07:57AM

Oct 17, 2024 07:50AM ZyVersa Therapeutics (ZVSA) CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

Oct 7, 2024 07:55AM

Aug 12, 2024 03:40AM

Aug 7, 2024 07:50AM

Jul 29, 2024 07:45AM

Jul 25, 2024 07:58AM

401,060 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All